Fusion Antibodies Announces Collaboration with Aerpio Therapeutics for Second Antibody Humanization Project

Share Article

UK-Based Antibody Engineering company Fusion Antibodies has today announced a second collaboration with Cincinnati-based research organisation Aerpio Therapeutics to apply its CDRx Antibody Humanization platform to Aerpio’s Mouse Monoclonal Antibody

Fusion Antibodies and Aerpio Therapeutics Logo
We are excited to have the opportunity to extend our collaboration with the team at Aerpio and look forward to delivering a panel of quality humanized antibodies using our CDRx platform.

Fusion Antibodies Ltd today announced a new collaboration with Cincinnati, OH-based biopharmaceutical company Aerpio Therapeutics, a biopharmaceutical company focused on advancing first-in-class treatments for the eye. Following the success of the companies’ first antibody development program, completed in 2015, Fusion Antibodies has now initiated a second antibody humanization program with Aerpio.

The partnership caps another record-breaking year for Fusion's Antibody’ Humanization Service. In the past 12 months over 30 projects have been completed. “We are excited to have the opportunity to extend our collaboration with the team at Aerpio and look forward to delivering a panel of quality humanized antibodies using our CDRx platform. The work Aerpio Therapeutics is doing on diabetic eye disease is cutting edge and very exciting to be a part of,” said Paul Kerr, Managing Director of Fusion Antibodies.

Kevin Peters, M.D., Aerpio Therapeutics’ Chief Scientific Officer, stated, “We’re pleased to begin our second antibody humanization program with Fusion Antibodies. The first project went very well and yielded multiple humanized clinical candidates. The success of the first program was a tribute to the experience and knowledge of the Fusion Antibodies team and to the collaborative nature of the Fusion culture.”

About Aerpio Therapeutics
Aerpio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of vascular disorders with an emphasis on diseases of the eye. Aerpio is a leader in the development of therapeutics based on Tie2 activation and the stabilization of hypoxia-inducible factor 1α (HIF-1α). The Company’s lead program, AKB-9778, is a first-in-class small molecule stabilizer of the Tie2 pathway and is in clinical development for diabetic eye disease. More information is available at http://www.aerpio.com.

About Fusion Antibodies
Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects. With 15+ years of experience in the medical research industry, including two Antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.

Fusion Antibodies has the knowledge and expertise to build and deliver a bespoke package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies, and using their next generation in silico CDRx™ technology, they have modernized the traditional CDR grafting technique. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic, and the in-house expertise at Fusion Antibodies ensures development success.

Visit http://www.fusionantibodies.com to find out more.

Contact Information
Fusion Antibodies Ltd
1 Springbank Road,
Springbank Industrial estate
BT17 0QL

Tel: +44 (0)28 90432800
E: info(at)fusionantibodies(dot)com
W: http://www.fusionantibodies.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Paul Kerr
Follow >
Fusion Antibodies
since: 02/2011
Like >
Follow us on